Fortis’ plan to divest a stake in its Singapore asset, RadLink-Asia Pte Ltd, and its subsidiaries to Medi-Rad Associates has hit a wall, with the country’s Competition Commission ruling against the deal.
In September 2014, Fortis had announced plans to sell 100 per cent of shareholding in Radlink-Asia and Radlink, Singapore, which engage in diagnostic and molecular imaging services, to Medi-Rad Associates, an indirect wholly-owned subsidiary of Malaysia-based IHH Healthcare Bhd for 137 million Singaporean dollars (over $108.5 million).
The Singaporean watchdog, however, has said the transaction could reduce competition in the market.
“Fortis continues to explore alternative value-unlocking opportunities related to RadLink, in furtherance of the company’s stated strategy to focus on India,” the company said in a statement on Friday.
The company has been on a divestment spree since 2013 and has sold several international assets, starting with Dental Corporation, Australia, in May 2013, for A$270 million (₹1,452 crore).
In August, the same year, Fortis sold its entire 65 per cent stake in Vietnam-based chain Fortis Hoan My Medical Corporation for $80 million; and Hong Kong-based Quality Healthcare for $355 million in October 2013.
The company’s shares fell on BSE on Friday, slipping 5.10 per cent, closing at ₹154.45 a piece.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.